Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACADNASDAQ:COGTNASDAQ:MORNASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$16.78+0.1%$18.46$14.15▼$20.68$2.80B0.432.56 million shs1.29 million shsCOGTCogent Biosciences$7.29-4.0%$8.07$5.73▼$12.61$864.12M1.81.25 million shs1.23 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ARYTMRhythm Pharmaceuticals$50.24-2.1%$56.17$35.17▼$68.58$3.24B2.3490,221 shs224,367 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+0.06%-4.71%-9.25%-2.78%-14.21%COGTCogent Biosciences-3.95%-1.62%-13.42%-10.55%+11.13%MORMorphoSys0.00%0.00%0.00%0.00%+5.10%RYTMRhythm Pharmaceuticals-2.10%-2.71%-12.75%-9.05%+22.63%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals4.4676 of 5 stars4.33.00.00.03.04.22.5COGTCogent Biosciences2.1606 of 5 stars4.41.00.00.02.00.00.6MORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/ARYTMRhythm Pharmaceuticals4.2931 of 5 stars4.52.00.04.32.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.53Moderate Buy$24.0043.03% UpsideCOGTCogent Biosciences 2.75Moderate Buy$14.4397.92% UpsideMORMorphoSys 0.00N/AN/AN/ARYTMRhythm Pharmaceuticals 2.92Moderate Buy$69.3137.95% UpsideCurrent Analyst Ratings BreakdownLatest COGT, RYTM, ACAD, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/7/2025ACADACADIA PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight$20.00 ➝ $20.003/7/2025COGTCogent BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/7/2025COGTCogent BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$17.003/7/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$72.00 ➝ $72.003/5/2025RYTMRhythm PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$78.003/3/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$69.00 ➝ $70.002/27/2025ACADACADIA PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$28.00 ➝ $28.002/27/2025ACADACADIA PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.002/27/2025ACADACADIA PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.002/27/2025COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.002/27/2025RYTMRhythm PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$80.00 ➝ $81.00(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M2.92N/AN/A$2.63 per share6.38COGTCogent BiosciencesN/AN/AN/AN/A$2.30 per shareN/AMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17RYTMRhythm Pharmaceuticals$130.13M24.41N/AN/A$2.87 per share17.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals-$61.29M$1.3621.5122.08N/A13.83%25.83%14.71%5/14/2025 (Estimated)COGTCogent Biosciences-$192.41M-$1.94N/AN/AN/AN/A-112.55%-60.44%5/6/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ARYTMRhythm Pharmaceuticals-$184.68M-$4.35N/AN/AN/A-230.07%-367.36%-77.47%5/6/2025 (Estimated)Latest COGT, RYTM, ACAD, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/26/2025Q4 2024RYTMRhythm Pharmaceuticals-$0.69-$0.72-$0.03-$0.72$38.48 million$41.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.292.11COGTCogent BiosciencesN/A6.446.44MORMorphoSys4.981.381.38RYTMRhythm PharmaceuticalsN/A3.493.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%COGTCogent BiosciencesN/AMORMorphoSys18.38%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals28.30%COGTCogent Biosciences5.92%MORMorphoSys0.05%RYTMRhythm Pharmaceuticals5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510166.79 million119.30 millionOptionableCOGTCogent Biosciences80113.85 million103.92 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableRYTMRhythm Pharmaceuticals14063.22 million58.02 millionOptionableCOGT, RYTM, ACAD, and MOR HeadlinesRecent News About These CompaniesStifel Nicolaus Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)March 11 at 7:16 PM | markets.businessinsider.comRhythm Pharmaceuticals' (RYTM) "Overweight" Rating Reiterated at Morgan StanleyMarch 10, 2025 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Recommendation of "Moderate Buy" by AnalystsMarch 9, 2025 | americanbankingnews.comRhythm Pharmaceuticals' (RYTM) "Overweight" Rating Reaffirmed at Morgan StanleyMarch 8, 2025 | marketbeat.comRhythm Pharmaceuticals assumed with an Overweight at Morgan StanleyMarch 7, 2025 | markets.businessinsider.comHC Wainwright Issues Positive Estimate for RYTM EarningsMarch 7, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Position Decreased by Candriam S.C.A.March 7, 2025 | marketbeat.comStifel Nicolaus Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)March 7, 2025 | americanbankingnews.comHC Wainwright Brokers Raise Earnings Estimates for RYTMMarch 7, 2025 | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Stifel NicolausMarch 6, 2025 | marketbeat.comFY2026 Earnings Forecast for RYTM Issued By HC WainwrightMarch 6, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for RYTM FY2026 Earnings?March 6, 2025 | americanbankingnews.comRhythm Pharmaceuticals resumed with a Buy at StifelMarch 6, 2025 | markets.businessinsider.comHC Wainwright Forecasts Strong Price Appreciation for Rhythm Pharmaceuticals (NASDAQ:RYTM) StockMarch 5, 2025 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by BrokeragesMarch 4, 2025 | marketbeat.comY Intercept Hong Kong Ltd Invests $328,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)March 4, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, HC Wainwright Analyst SaysMarch 3, 2025 | marketbeat.comRhythm Pharmaceuticals price target raised to $70 from $69 at H.C. WainwrightMarch 3, 2025 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $81.00February 28, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Earns Buy Rating from Needham & Company LLCFebruary 28, 2025 | marketbeat.comRhythm Pharmaceuticals price target raised to $81 from $80 at CanaccordFebruary 28, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPrice Targets on NVIDIA Rise in Front of EarningsBy Sarah Horvath | February 24, 2025View Price Targets on NVIDIA Rise in Front of EarningsWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Hidden AI Play: The Truth Behind Its WeRide InvestmentBy Gabriel Osorio-Mazilli | February 14, 2025View NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide InvestmentArcher Aviation Stock Skids: Mistaking Progress for Bad News?By Chris Markoch | February 24, 2025View Archer Aviation Stock Skids: Mistaking Progress for Bad News?4 EV Stocks Facing Uncertainty—Which Ones Will Survive?By Thomas Hughes | March 7, 2025View 4 EV Stocks Facing Uncertainty—Which Ones Will Survive?COGT, RYTM, ACAD, and MOR Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$16.78 +0.01 (+0.06%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$17.16 +0.38 (+2.29%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Cogent Biosciences NASDAQ:COGT$7.29 -0.30 (-3.95%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$7.01 -0.28 (-3.84%) As of 07:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 03/12/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Rhythm Pharmaceuticals NASDAQ:RYTM$50.24 -1.08 (-2.10%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$51.30 +1.06 (+2.10%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Deal With Archer Aviation Keeps AI’s Future in Focus Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount? Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
